New drug LY4268989 tested in healthy people for safety and processing

NCT ID NCT06964776

Completed Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed Phase 1 trial tested the drug LY4268989 (MORF-057) in 144 healthy volunteers, including Japanese and Chinese participants. The main goals were to measure how the body absorbs and processes the drug, check for side effects, and see how food or other drugs (like midazolam) affect it. This early study does not test whether the drug treats any disease, but provides important safety and dosing information for future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY4268989 (MORF-057)
What this could lead to: If successful, this study could provide the safety and dosing data needed to move LY4268989 into trials for a specific disease.
What could go wrong: This is a very early Phase 1 study in healthy people, so it cannot show whether the drug works for any disease. The results may not predict effects in patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Show contact details

Locations

CenExel ACT

Anaheim, California, 92801, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.